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GABRIELLA HARTMAN: REGULATING NEURONAL GROWTH WITH 
STRUCTURALLY DEFINED GLYCANS 
(Under the direction of Dr. Nicole Ashpole) 
 
Chondroitin sulfate proteoglycans (CSPGs) and keratan sulfate proteoglycans 
(KSPGs) play an important role in neural development. Aggrecan, a CSPG, operates in 
the neural extracellular matrix where it negatively regulates neurite outgrowth to prevent 
aberrant process formation. Unfortunately, this aggrecan or CSPG-rich/KSPG-rich barrier 
can also prevent neuronal regeneration, which contributes to the inability to repair brain 
and spinal cord injuries. Removal of CSPGs and KSPGs has been shown to increase 
neurite outgrowth. We extend these findings by testing the ability of structurally-defined 
glycans to outcompete aggrecan and allow neurite outgrowth. Our overall goal is to 
determine if there is a particular glycan structure which can overcome inhibitory CSPGs 
and KSPGs without inhibiting neurite outgrowth themselves. We utilized primary 
cultures of rat neurons and applied polydisperse-related mixtures of CSPGs, KSPGs and 
newly-isolated, novel glycans in the absence and presence of aggrecan. Several of these 
glycans successfully removed the aggrecan-induced blockade while not inhibiting neurite 
outgrowth on their own. We are currently investigating the efficacy of these compounds 
in concentration-response curves and are testing additional glycans with different 
molecular weights and varying sulfation patterns to determine the structural requirements 
for the glycans as modulators of neurite outgrowth. By investigating the impacts of these 
glycans, we will increase the understanding of proteoglycan regulation of neural structure 
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 When the body is injured, natural defenses begin to work to repair the damaged 
tissue. Inflammation, white blood cells, and a multitude of other factors combine to repair 
the damaged site. As with many tissues, a scar will form following injury (Beller, 2014). 
Traumatic brain injury (TBI) or spinal cord injury (SCI) lead to the formation of specific 
type of scar tissue called glial scars, which are comprised of complex molecular 
interactions and are poorly understood. Glial cells, the principal cells responsible of the 
formation of glial scars, are a group of essential cells within the nervous system that 
respond to injury and provide structural and metabolic support. Glial cells include 
astrocytes, oligodendrocytes, and microglia. Following a SCI, specialized astrocytes will 
coordinate the healing process and form the glial scar along with connective tissue. 
Previous studies have shown the importance of the response of glial cells to injury and 
the implications for permanent damage as a result. The glial scar acts as a protective, yet 
inhibitory barrier, preventing regeneration of the spinal cord, ultimately leading to 
permanent effects like paralysis (Daniell, 2012). Though it was commonly thought before 
that the glial scar was a mechanical barrier to neuronal regeneration, it is now understood 
that the upregulation of certain molecules in the glial scar may allow for neuronal 
regeneration (Daniell, 2012). Because both TBI and SCI result in axonal injury, it is 
thought that identification of molecules or mechanisms that permit axonal repair through 
the scar may have the potential to improve outcomes following these injuries (Harris, 
2009).  
A major factor contributing to the inhibition of neurite outgrowth and regeneration is 
the upregulation of inhibitory chondroitin sulfate (CS) and keratan-sulfate (KS) 
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proteoglycans (CS/KSPGs) following a traumatic injury. Proteoglycans are glycoproteins 
that have glycosaminoglycans (GAGs) attached and are a key component in the 
extracellular matrix (ECM). They comprise nearly 20% of the ECM and are known to 
have a role in the progression of disease, cell proliferation, and nervous system 
development (Djerbal, 2017). GAGs are highly anionic linear polymers composed of 
disaccharide units of either uronic acid or galactose and a hexosamine (Pomin, 2012). 
CSPGs contain a carbohydrate chain with alternating N-acetylgalactosamine (GalNAc) 
and glucuronic acid (GlcA) units with varying sulfation patterns, whereas KSPGs are 
poly-N-acetyllactosamine chains (Varki, 2017). Together, CS/KSPGs also have glycan 
chains varying in size, number, and sulfation patterns which allow for vast diversity in 
the effects of CS/KSPGs on neurite regeneration and rehabilitation. Proteoglycans can 
affect neurite outgrowth through interactions of the core protein and the GAG chains. 
These interactions regulate various physiological processes such as inflammation, 
metastasis, development, regeneration, coagulation, cell adhesion, growth, and neuronal 
regeneration (Pomin, 2012). Though both core protein and GAG chain interactions have 
been shown to impact neuronal growth, the mechanism by which these affect neuronal 
regeneration is not well understood (Beller, 2014). However, the regulation of neurite 
outgrowth is thought to be receptor mediated mechanisms – likely through RTN4R, 
RTN4RL1, PTPRF, etc. It is unclear whether the CS/KSPGs interact with the receptor 
either directly or indirectly (Daniell, 2012). Regardless, upregulation of proteoglycans 
following injury in the CNS is indicative of decreased neurite outgrowth and a 
nonpermissive growth environment, providing an opportunity for the introduction of a 
possible therapeutic intervention (Daniell, 2012). 
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Although the mechanism of CS/KSPGs and its inhibitory effects on neuronal 
plasticity is largely unexplored and not completely understood, there is evidence that 
disruption of the CS/KSPG interactions will increase neurite outgrowth and regeneration. 
Aggrecan from bovine cartilage (a CS/KSPG) sufficiently inhibits axon outgrowth in an 
in vitro culture model, and this inhibitory effect is lost following digestion of the CS 
GAG chain or by alterations of the core protein (Ohtake, 2015). When aggrecan binds to 
hyaluronic (HA), an important component of articular cartilage, large negatively charged 
aggregates are formed (Figure 1) (Holmes, 1988). The ability of aggrecan to form 
aggregates of hyaluronan (HA) and other properties are attributed to its high content of 
CS (Collin, 2017). But, since aggrecan contains little KS, it is likely that the ability of 
CS/KSPGs to inhibit neurite regeneration is due to the proper spatial presentation of both 
KS and CS.  
There is considerable diversity in glycan structure found in nature and it is known that 
sulfated glycans from marine life have the potential biotherapeutic functions in the 
organisms that produce them and exogenously in other organisms (Pomin, 2014). 
Sulfated fucans from sea urchin egg jelly express variability in structure and sulfation 
patterns among species. This species-specific differentiation regulates fertilization by 
inducing an acrosomal reaction with only compatible sperm. Thus, structural changes in 
glycans of the sea urchin egg jelly may lead to speciation and evolutionary changes, as 





Figure 1: Structure of Aggrecan. Source(s): Millipore Sigma, [Structural Proteins – 
Aggrecan]. Retrieved from https://www.sigmaaldrich.com/life-science/metabolomics/ 




GAGs N-linked Glycans 
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We sought to examine whether novel glycans isolated from these sources can 
outcompete CS/KSPGs such as aggrecan and ultimately regulate neuronal growth. To do 
this, unique glycans from Lytechinus variegatus (L. variegatus) and Echinometra 
lucunter (E. lucunter) were investigated in their effect on neuronal growth and 
competition with CS/KSPGs. Two glycans were extracted and tested from the egg jelly of 
L. variegatus, LVP1 and LVP2, and one glycan was extracted from E. lucunter, along 
with their low molecular weight derivatives. LVP1 is a high molecular polymer of [L-
Fucp4(SO3-)-α(1-3)-L-Fucp2,4(SO3-)-α(1-3)-L-Fucp2(SO3-)-α(1-3)-L-Fucp2(SO3-)]n. 
The presence of electrostatic repulsion of the sulfates in the linking disaccharide [-3)-α-
L-Fucp-2(OSO3)-(1–3)-α-L-Fucp-4(OSO3)-(1-] between the tetrasaccharides accounts 
for the increased motion in the glycan structure (Queiroz, 2015). LVP2 is a high 
molecular weight polymer composed of [L-Fucp4(SO3-)]n, while the glycan from E. 
lucunter is composed of [L-Gal2(SO3-)]n. All native forms are close to 100 kDa. Low 
molecular weight derivatives were acquired by hydrolysis of native glycans. Hydrolyzed 
E. lucunter glycans (ELHD) are composed of 60% [→3)-a-galactose(2SO3-)-(1→]n and 
40% [→3)- a-galactose-(1→]n, and hydrolyzed LVP2 (LVP2HD) are composed of 80% 
[→3)- a-fucose(4SO3-)-(1→]n and 20% [→3)- a-fucose-(1→]n and 20% [→3)- a-
fucose-(1→]n. Therefore, the low molecular weight derivatives contain essentially the 
same structure as the native form, but with less sulfation. 
 CS, the core protein of CSPGs, is the most abundant GAG endogenously 
produced in the central nervous system and consists of repeating disaccharide units of D-
glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc). Various positions of CS 
may be sulfated, giving rise to different residues of CS. For example, sulfation of C-4 of 
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GalNAc gives rise to CS-A, C-6 of GalNAc gives rise to CS-C, C-2 of GlcA and C-6 of 
GalNAc gives rise to CS-D, and C-4 and C-6 of GalNAc gives rise to CS-E (Djerbal, 
2017). The sulfation patterns are vital to consider when investigating the interactions 
between glycans of CS/KSPGs and neurons (Queiroz, 2015). Thus, prior to testing the 
functional effects of these glycans in our neuron cultures, our collaborators conducted 
NMR analysis to verify sulfation patterns, thereby allowing us to determine structure-
function relationships. It was determined that the CS preparation was approximately 50% 
non-sulfation and approximately 50% 6-sulfation, indicating our novel glycans primarily 
featured CS-C. 
Other factors that influence glycan interactions with target cells are glycan 
dynamics and conformation; however, little information on this is known on the exact 
size and shape required for regulating neurons. There is a vast amount of diversity in 
glycan size, shape, and sulfation pattern observed in nature. We set out to assess the 
conformations and sulfation patterns may be serve as important biological regulators 
within the ECM. We hypothesize that specific sulfated glycans isolated from sea urchins 
will outcompete aggrecan and allow neurite outgrowth and that disruption of CSPG 
and/or KSPG signaling will promote axonal regeneration. We tested a variety of 
mammalian and marine sulfated glycans with unique structures and examined their 
impact on neurite outgrowth. As controls, chondroitin sulfate (CS), chondroitinase, 
enoxaparin, and heparin were examined as studies have shown that enzymes such as 
keratanase and chondroitinase, as well as low molecular weight glycans prove to 
effectively inhibit CS/KSPGs are restore growth following a SCI (Barriett et al., 2006, 
Kim et al., 2006). Examining the both protein-GAG interactions and sulfation patterns in 
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our neuronal growth assays may provide insight on the molecular mechanisms underlying 
the regulation of neurite growth and regeneration (Pomin, 2012). This comprehensive 
study of novel glycans, proteoglycan regulation, and growth of neurite processes has the 
potential to provide insight into the mechanism by which CS/KSPGs operate and be a 






















All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Mississippi and performed in accordance with 
their approved guidelines. Timed-pregnant Sprague Dawley rats were ordered from 
Envigo and arrived into the UM animal care facility at 17 days postcoitum and were 
temporarily housed with access to food (Teklad 7001) and water ad libitum until the time 
of euthanasia (described below). Cerebral tissue of both male and female pups were 
utilized in the study.  
Coating Plates 
96-well or 24-well plates were precoated with 0.01% Poly-L-Lysine (PLL) prior 
to starting cell culture to give the neurons a surface to attach to in the wells. After 24 
hours in an incubator, the PLL was removed and washed 3 times with HPLC-grade water. 
The plates were then treated with aggrecan and/or the novel glycans at various 
concentrations, as indicated on the respective figures. The plates with glycans were then 
incubated at 37°C for 4 hours to allow adherence. The treatment was removed, and the 
plates were washed with HPLC water three times, vacuuming off the HPLC water after 
each wash. 
Culturing Neurons 
Pregnant Sprague Dawley rats were euthanized 17 days postcoitum with 
isoflurane anesthesia followed by cervical dislocation. The ventral side of the rat was 
then cleaned with ethanol. The embryos were removed and placed into a 10 cm dish on 
ice with Hank’s Balanced Salt Solution (HBSS). To extract the neurons, a midsagittal 
 9 
incision was made down the brain and transversely across the occipital bone.  After 
extracting the brain from the embryos, the hemispheres were separated, the meninges 
were removed, and then placed into 15mL conical with 1X HBSS. HBSS was then 
removed and added Papain/HBSS solution for 20-25 minutes in the incubator to 
enzymatically digest the tissue. After incubation, Papain/HBSS solution was removed. 
The neurons were washed with pre-warmed Neurobasal media, 45 mL FBS, L-
Glutamine, and 5 mL pen strep three times before being titurated with media using a 
glass pipette. The supernatant was run through the filter and remaining brains were 
titurated two more times. The neurons were plated with a cell density of 250,000 
cells/cm2 in each pre-treated well, then incubated at 37°C in the presence of 5.0% CO2 
for 24 hours. After 24 hours, the media was replaced with new neurobasal media with 
B27 supplement, L-Glutamate, and 5 mL pen strep and continued to incubate for another 
24 hours (Ashpole, 2011). After culturing neurons on the pre-treated plates, they were 
placed in an incubator at 37°C and 5% CO2 for 48 hours. 
Immunostaining Cells 
Forty-eight hours after incubation, cells were fixed with 4% paraformaldehyde 
(PFA) in phosphate buffer for 20 minutes and permeabilized with 0.1% Triton X-100 in 
PBS for 20 minutes. Then, cells were blocked with 0.1% Triton X-100 in PBS with 5% 
bovine serum albumin (BSA) for 1 hour, immunostained with anti-β-Tubulin antibody 
(Cell Signaling Technology, Rabbit mAb, 2128S, 1:100) in PBS overnight at 4°C. 
Following removal of the primary antibody, the wells were washed 3 times with PBS for 
5 minutes and treated for 1 hour in the dark with a 488 nm fluorescent goat anti-rabbit 
(ThermoFisher, 1:1000). Plates were then rinsed three times with PBS for 5 minutes and 
 10 
treated for thirty minutes in the dark with DAPI (ThermoFisher, EN62248, 1:1000). 
Plates were again rinsed three times with PBS for 5 minutes and stored in PBS.  
MTS Assay 
 CellTiter 96Ò AQueous One Solution Reagant was used to perform the MTS to 
determine the viability of the cells left on the plate following treatment. Active cells will 
metabolize the reagent and change it to formazan, thus changing the color form a pale 
yellow to a dark purple, allowing detecting of viable cells with visible light. The reagent 
includes tetrazolum, as well as electron coupling reagents to reduce the reagent to 
eventually form the indicative formazan (Riss, et al., 2013). After the CellTiter 96Ò 
AQueous One Solution Reagant was added to the wells, the plates were placed in the 
incubator for 1-2 hours once an obvious color change from pale yellow to dark purple 
was observed. The plate was then placed in a plate reader and read at an absorbance of 
490 nm.  
Gene Expression 
 A subset of cells was grown for seven days to examine long-term changes in 
structure and gene expression. These cells were cultured on 6cm round dishes until RNA 
was isolated using the RNeasy kit. For this, 350 µl of Buffer RLT was added per dish. 
Plates were scraped and the cells and Buffer RLT were pipetted in spin columns. Samples 
were centrifuged for 15 seconds at 8000 x g and flow through was discarded. 700 µl of 
Buffer RW1 was added and centrifuged for 15 seconds at 8000 x g, then flow through 
was discarded. Then, 500 µl of Buffer RPE was added to the spin columns and 
centrifuged at 8000 x g for 15 seconds. This step was repeated, but the samples were 
centrifuged for 2 minutes instead. Flow through was discarded between each step. 
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Samples were then centrifuged again at full speed for 1 minute to dry the membranes. 
Following this, approximately 50 µl of RNase-free water was added to the spin column, 
and samples were spun in the centrifuge at 8000 x g for 1 minute to remove the RNA 
from the column. Nanodrop RNA was used to identify concentration and purity of 
samples. Then, Applied Biosystems High Capacity RNA-to-cDNA Kit was used to 
convert RNA samples to cDNA, and TaqMan Universal PCR Master Mix and TaqMan 
gene specific primers (PTPRS, PTPRF, RTN4R, RTN4RL1, RTN4RL2) were used to run 
a real-time PCR and was ran for 40 cycles.  
Imaging 
Following staining, multi-well plates were imaged on a High Content Analysis 
Nikon Ti2-E Microscope with CSI S Plan Fluor ELWD 20x Ph1 ADM objective with 
DAPI (395 nm) and FITC (470 nm) fluorescent filters, or with Plan Apo l 60x Oil 
objective with DAPI (395 nm), FITC (470 nm), and TRITC (532 nm) fluorescent filters 
with 200 ms exposure. Image locations were selected at random.  
Image Analysis 
All data was saved and exported using Excel (Microsoft Office, 2016). Sholl 
Analysis was used to trace neurites and count number of neurite crossings (Figure 2). 
Concentric ring distance was then used to generate a curve and calculate the area under 
the curve as a representation of total neurite outgrowth (ImageJ).  
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Figure 2: Representative image of steps of Sholl analysis to assess total neurite 
outgrowth as stated above. ImageJ was used to trace all processes of neuron, with 
primary process in green and additional processes in purple. Concentric ring distance was 
then used to assess total crosses over a certain distance, followed by various calculations 
and area under the curve analysis.  
Tracing Concentric Rings 
Analysis: 
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Nikon Elements Analysis software object count was used to measure the total 
percent area of green fluorescence (neurites) and normalized it to blue fluorescence 
(nuclei) to confirm the total neurite outgrowth (NIS Elements AR Analysis, Version 
5.02). SigmaPlot was used to create all graphs and run statistical analysis (Systat 
Software, San Jose, CA). In the graphs, error bars were used to represent plus/minus 
standard error measurement (± SEM) in cases where data was averaged.  
Statistical Analysis 
The data was evaluated by one-way analysis of variance (ANOVA) using 
multiple groups. A Dunnett’s post hoc test using SigmaPlot was also used to verify 
statistical significance of groups in comparison with the control (Systat Software, San 
Jose, CA). All data was normalized to the control in SigmaPlot. Curve fitting was done 
using a 4-parameter logistic sigmoidal curve. Results were considered statistically 









Neuron cultures were established from rat cortices and grew cell in vitro for two 
days following treatment of plates for 48 hours with varying concentrations of aggrecan. 
After developing neurons in culture, the neurons were fixed with paraformaldehyde and 
stained using immunocytochemistry techniques and then imaged. Total neurite growth 
was assessed using various methods of analysis to confirm aggrecan inhibits neuronal 
growth at increasing concentrations, as previously demonstrated in other publications 
(Johnson, 2002). Sholl analysis was used to determine what concentration of aggrecan 
statistically significantly inhibits neuronal growth (Figure 3C). Because each row of the 
24-well plate was treated with a different concentration of aggrecan, the graph represents 
the average area of neuron processes per nuclei. All data was normalized to the control. 
As the concentration of aggrecan increased, there was a significant decrease in neurite 
outgrowth at 5.0, 7.5 and 10.0 micrograms/milliliter of aggrecan. Further analysis of total 
neurite growth following with increasing concentrations of aggrecan was assessed using 
area of neurite coverage and longest neurite quantification, and the results indicated that 
7.5 and 10.0 micrograms/milliliter of aggrecan significantly inhibited neurite outgrowth 
(Figure 3D-E). From this, it was determined that 10 micrograms/milliliter of aggrecan 
would be used as a standard concentration of aggrecan in this experiment. All other 
treatments with aggrecan therefore have a concentration of 10 micrograms/milliliter 
unless stated otherwise. 
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Figure 3: Increasing concentration of aggrecan exhibited neurite outgrowth inhibition, 
while known glycans do not inhibit neurite outgrowth. (a) cortical neuron cells were 
cultured at 250,000 cells/cm2 and treated with 10 µg/mL aggrecan. Neurons were fixed 
and stained with b-tubulin (green) and DAPI (blue). Scale bar represents 50 µm. (b) 
cortical neurons treated with water for control, scale bar represents 50 µm.  (c) Sholl 
analysis of neurons treated with water, 5 µg/mL, 7.5 µg/mL, and 10 µg/mL of aggrecan. 
*, p <0.05, n=12 (d) area analysis of cortical neurons treated with water, 5 µg/mL, 7.5 
µg/mL, and 10 µg/mL of aggrecan. *, p <0.05, n=12 (e) neurite length of cortical neurons 
treated with water, 5 µg/mL, 7.5 µg/mL, and 10 µg/mL of aggrecan. *, p <0.05, n=12 
Representative images of cortical neurons treated with chondroitin (f), chondroitinase (g), 
and heparin (h). Scale bars represent 50 µm. (i) cell count normalized to control of known 
glycans chondroitin, chondroitinase, enoxaparin, and heparin. n=8-16 (j) MTS 
absorbance assay of known glycans to test for toxicity, n=8 (k) area analysis of known 
glycans normalized to control, n=8-16 
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 In comparison to aggrecan’s inhibitory effect on neurite outgrowth, cortical 
neurons treated with 10 micrograms/milliliter of known glycans alone revealed that these 
glycans do not inhibit neurite outgrowth, nor did these glycans decrease number of nuclei 
(Figure 3I, K). An MTS absorbance assay was also conducted on cells treated with these 
glycans to further to assess viability, and results support that these glycans had no 
toxicity effects on the neurons (Figure 3J).  
 Novel sulfated glycans from marine life were then applied to the culture plates 
(10 micrograms/milliliter) prior to the addition of cortical neurons. These novel glycans 
and derivatives were provided by Dr. Vitor Pomin. Forty-eight hours after plating 
neurons were analyzed by cell count, area analysis, and for neuronal viability to confirm 
that novel glycans alone did not contribute to toxicity for neurons (Figure 4G, H, I). 
Results showed that novel glycans did not significantly alter number of nuclei, nor did 
they contribute to toxicity. LVP2HD did, however, show an increase in metabolic activity 
compared to other glycans (Figure 4H). Additionally, novel glycans did not exhibit a 
decrease in total processes following area analysis, and treatment of ELHD, LVP1HD, 
and LVP2HD alone, without the presence of inhibitory molecules showed a significant 
increase in total processes per cell (Figure 4I). Structures of novel glycans are exhibited, 
with R in E. lucunter representing at sulfated group in EL, and is 60% sulfated in ELHD. 
R in LVP2 represents a sulfate group, while being 80% sulfated in LVP2HD (Figure 4A, 
B, C). Sulfation patterns for LVP1HD exhibit undefined selective sulfation. 
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Figure 4: Novel sulfated glycans do not inhibit neurite outgrowth. (a) structure of a-
galactose 2 sulfate glycan from E. lucunter, R=60% OSO3- and 40% H for ELHD. (b) 
structure of novel glycan from LVP1 (c) structure of 3-linked 4-sulfated a-fucan glycan 
from LVP2, R=80% OSO3- and 20% H for LVP2HD. Representative images of cortical 
neurons treated with 10 µg/mL of E.L (d), LVP1HD (e), and LVP2HD (f). Scale bars 
represent 50 µm. (g) nuclei count of cortical neurons treated with 10 µg/mL of novel 
glycans, n=8 (h) MTS absorbance assay of cortical neurons treated with 10 µg/mL of 
novel glycans, *, p<0.05, n=8 (i) area analysis of cortical neurons treated with 10 µg/mL 
of novel glycans, *, p<0.05, n=8 
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Next, the protective ability of various novel glycans were tested against 10 
micrograms/milliliter of aggrecan at the same concentration used in Figure 4 to 
demonstrate the ability of novel sugars to outcompete aggrecan. Images were analyzed 
using sholl analysis and nuclei count. After completing sholl analysis, the number of 
neurite crossings from the soma were plotted, then the area under each curve was 
integrated and calculated to generate a bar graph. For these sets of data, an ANOVA 
statistical analysis was run with a Dunnett’s post hoc test to determine which glycans 
significantly outcompeted aggrecan’s inhibitory influence on the neuron culture. Again, 
all data was normalized to control and error bars representing ± SEM. Sholl analysis 
revealed that EL, ELHD, LVP1HD, LVP2, and LVP2HD, statistically outcompeted 
aggrecan and allowed for neurite growth (Figure 5E). Additionally, nuclei count of 
neurons treated with both novel glycans and aggrecan was conducted (Figure 5F). From 
this, it was determined that LVP1HD and LVP2HD allowed for an increase in nuclei 
count as well.  
Following this, it was hypothesized that these novel glycans allow for neurite 
outgrowth in a concentration dependent manner (Snow, 1992). Before beginning 
concentration response curves with the novel glycans, potency of chondroitin on neuronal 
growth was tested, as it has been previously published in literature that chondroitin 
allows for growth in a concentration-dependent manner. Various concentrations of 




Figure 5: Novel glycans outcompete aggrecan. Representative images of cortical neurons 
treated with 10 µg/mL aggrecan (a), 10 µg/mL aggrecan + 10 µg/mL ELHD (b), 10 
µg/mL aggrecan + 10 µg/mL LVP1HD (c), and 10 µg/mL aggrecan + 10 µg/mL 
LVP2HD (d). Scale bars represent 50 µm. (e) area under the curve from sholl analysis of 
cortical neurons treated with 10 µg/mL aggrecan + 10 µg/mL novel glycans; *, p< 0.05, 
**, p>0.001, n=12 (f) nuclei count of cortical neurons treated with 10 µg/mL aggrecan + 




Concentrations of 0.15625 to 20.0 micrograms/milliliter of chondroitin was 
applied and data was assessed again using a one-way ANOVA with Dunnett’s post hoc 
test vs control. All data was normalized to control. From this assay, it was determined 
that concentrations exceeding 2.5 (5.0, 10.0 and 20.0) micrograms/milliliter of 
chondroitin were significant concentrations that allowing for neurite outgrowth and 
arborization. The potency of chondroitin in the presence of 10 micrograms/milliliter of 
aggrecan was then assessed (Figure 6F). Concentrations of 0.15625-20.0 
micrograms/milliliter of chondroitin was applied with 10 micrograms/milliliter of 
aggrecan. Data was normalized to the control and was tested for significance with a one-
way ANOVA with a Dunnett’s post hoc test. Similar to when chondroitin was tested 
without aggrecan, chondroitin concentrations of 5.0, 10.0, and 20.0 
micrograms/milliliters significantly increased neurite growth by outcompeting 10.0 
micrograms/milliliters of aggrecan, with 20 micrograms/milliliter of chondroitin having a 
p value <0.001.  
After determining from the sholl analysis that LVP2 significantly impacted total 
neurite outgrowth, LVP2 became our key glycans of interest and was further studied later 
with concentration-response curves. Similar to the chondroitin, LVP2 alone was applied 
at various concentrations to neurons, and viability was assessed using a one-way 
ANOVA with a Dunnett’s post hoc test (Figure 6H). 
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Figure 6: Concentration dependent response of chondroitin and LVP2 on cortical neurite 
outgrowth. Representative images of cortical neurons treated with water for control (a), 5 
µg/mL chondroitin (b), 10 µg/mL chondroitin (c), and 20 µg/mL chondroitin (d). Scale 
bars represent 100 µm. (e) area analysis of chondroitin concentration curve, *, p <0.05, 
n=8 (f) area analysis of chondroitin + 10 µg/mL aggrecan concentration curve, *, p 
<0.05, **, p<0.001, n=8 (g) area analysis of LVP2 + 10 µg/mL aggrecan concentration 
curve, *, p <0.05, **, p<0.001, n=8 (h) nuclei count of LVP2 + 10 µg/mL aggrecan 
concentration curve, *, p <0.05, **, p<0.001, n=8 
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It was determined that 2.5 and 5.0 milligrams/milliliter of LVP2 significantly 
increased the number of nuclei, with a p value of <0.05, while 10.0 and 20.0 
milligrams/milliliter of LVP2 significantly increased the number of nuclei as well with a 
p value of <0.001. The same concentrations of LVP2 were again applied to cortical 
neurons, but with the presence of 10.0 micrograms/milliliter of aggrecan (Figure 6G). 
Again, data was assessed with area analysis and statistical analysis was conducted with a 
one-way ANOVA with Dunnett’s post hoc test. Concentrations of 1.25, 2.5, 5.0, and 10.0 
micrograms/milliliter of LVP2 significantly outcompeted aggrecan to allow for neurite 
outgrowth. However, 20.0 micrograms/milliliter exhibited a decrease in total processes.  
 Because of the protective ability the novel glycans exhibited for neurite growth in 
the presence of aggrecan, the impact of glycans and aggrecan on size and shape of growth 
cones was tested (Figure 7). It was hypothesized that increases growth cone size might 
have implications for permissive growth environment. 
 Cortical neurons were treated with increasing concentrations of aggrecan, stained 
and imaged to view growth cones (Figure 7D). Growth cone size was assessed using 
ROI analysis. Following this, it was determined that increasing concentrations of 
aggrecan exhibited decreased size in growth cones, and 10.0 micrograms/milliliter of 
aggrecan exhibited significant decrease of growth cone size. Following this, it became 





Figure 7: Analysis of growth cones on cortical neurons treated with aggrecan and novel 
glycans. Representative images of growth cones on cortical neurons treated with water 
(a), 10 µg/mL aggrecan (b) and 10 µg/mL aggrecan + 10 µg/mL LVP1HD. Scale bars 
represent 10 µm, neurons were fixed and stained with b-tubulin (green), DAPI (blue), 
and phalloidin (red). (d) growth cone area analysis done by ROI analysis of cortical 
neurons treated with water, 5 µg/mL, 7.5 µg/mL, and 10 µg/mL of aggrecan. *, p <0.05, 
n=24 (e) growth cone area analysis done by ROI analysis of cortical neurons treated with 




 Assessment of growth cone size of glycans in the presence of 10.0 
micrograms/milliliter of aggrecan was then conducted to determine if glycans 
outcompeted aggrecan to an extent that exhibited significant increase in growth cone size 
(Figure 7E). Analysis was conducted using a one-way ANOVA was a Dunnett’s post 
hoc test, and all glycans tested, except for ELHD, showed significant increases in growth 
cone size compared to neurons treated solely with aggrecan.  
 Additional analysis of neurons treated with aggrecan for one week, instead of 48 
hours, was conducted to assess if aggrecan continued to exhibit its inhibitory effects of 
total neurite outgrowth in a long-term effect (Figure 8A). After conducting a one-way 
ANOVA, it was found that 5.0, 7.5, and 10.0 micrograms/milliliter of aggrecan exhibited 
a significant decrease in neurite outgrowth even one week after plating, thus supporting 
that the effects of aggrecan on neurite outgrowth are both immediate and long-term.  
 The mRNA expression of pathways that allow for neurite outgrowth was assessed 
using qPCR. Specifically, expression of PTPRS, PTPRF, RTN4R, RTN4RL1, and 
RTN4RL2 was examined in 7-day old neurons to possible determine what mechanism 
lies behind the glycans that provide the best potential for neurite growth, plasticity, and 
differentiation. Gene expression fold change was normalized to GAPDH for comparison 
of gene expression levels, and neurons were assessed in comparison to either water for 










 Figure 8: 7-day growth analysis (a) area analysis of cortical neurons treated with water, 
5 µg/mL, 7.5 µg/mL, and 10 µg/mL of aggrecan for one week. *, p <0.05, n=8 
Representative images of cortical neurons treated with water (b) and 10 µg/mL of 
















Figure 9: Gene expression fold change normalized to GAPDH on water, chondroitin, and 








Chondroitin was utilized for comparison in gene expressed due to copious 
amounts of previous literature confirming our findings of its growth permitting 
properties. LVP2HD had proven to provide the greatest growth permission of all glycans 
testing, making it the reason why it was also a candidate for gene analysis.  
PTPRS and PTPRF are genes that regulate a variety of cellular processes such as 
cell growth, differentiation, cell-to-cell interaction, axon generation, and axon guidance 
(Shen, 2009). Nogo 66 receptors such as RTN4R, RTN4RL1, and RTN4RL2 are 
responsible for encoding the receptor that medicates axonal regeneration and plasticity in 
the CNS (Fournier, 2001). Data was normalized to control and following analysis it was 
determined that there was no difference in PTPRS, PTPRF, RTN4R, RTN4RL1, and 
RTN4RL2 between control, chondroitin, and LVP2HD. 
In addition to the novel glycans from the marine organisms, a preliminary study to 
examine the effect of chondroitin sulfates with varying lengths on neurite outgrowth was 
conducted. The goal was to determine if oligosaccharides [n] residues in length would 
have an impact on neurite outgrowth, or if there was a correlation in length and neurite 




Figure 10: Chondroitin sulfates at varying [n]’s weight analysis. Representative images 
of cortical neurons treated with water for control (a), 10 µg/mL aggrecan (b), and 10 
µg/mL DP4 (992 g/mol) chondroitin (c). Scale bars represent 100 µm. (d) area analysis of 
chondroitin sulfates with varying lengths impact on cortical neurite outgrowth alone, 
n=8-16 (e) area analysis of chondroitin sulfates with varying lengths impact on cortical 
neurite outgrowth in presence of 10 µg/mL aggrecan, *, p <0.05, n=8-16 (f) MTS 
absorbance assay for toxicity assay on 10 µg/mL chondroitin sulfates with varying 
lengths, n=8-16   
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Partially depolymerized chondroitin sulfates from 503 g/mol to 3472 g/mol, as 
well as full length CS and KS were applied to cortical neurons without the presence of 
aggrecan, and total neurite outgrowth was assessed using area analysis with one-way 
ANOVA and Dunnett’s post hoc versus control (Figure 10D). One-way ANOVA failed 
amongst all groups and showed no significant impact on neurite outgrowth. Area analysis 
was conducted on cut chondroitin sulfates in the presence of aggrecan, with a one-way 
ANOVA with Dunnett’s post hoc test versus aggrecan for control (Figure 10E). 
Following analysis, full length CS and 992g/mol partially depolymerized chondroitin 
sulfate exhibited significant increases in total neurite outgrowth in the presence of 
aggrecan.  
An MTS absorbance assay was also conducted on the partially depolymerized 
chondroitin sulfate to confirm that none of the samples showed toxicity to neuronal 
outgrowth (Figure 10F). A one-way ANOVA with a Dunnett’s post hoc test versus 









The data show that several novel sulfated glycans provided rescuing effects on 
neurite outgrowth in vitro against aggrecan. Additionally, the novel glycans exhibited 
increasing neurite outgrowth in a concentration dependent manner. The overall increase 
in axonal growth in the presence of both aggrecan and novel glycans suggest that the 
glycans allow the environment to be growth permissive, indicating that the glycans may 
provide a potential window for plasticity following the upregulation of KS/CSPGs with 
injury. Data from chondroitin sulfates with varying [n] residues indicate that size of 
glycan and neurite outgrowth are not related.  
 In accordance with the growth cone data, increasing concentrations of aggrecan 
lead to smaller growth cones, while nearly all neuron cultures treated with aggrecan and 
novel glycans exhibited a significant increase in growth cone size and shape. Previous 
studies have confirmed that CS/KSPGs stop or stall the development of growth cones and 
act as a barrier to growth cone advances (Snow et al., 1990, Wu et al., 1992). This growth 
inhibitory mechanism may be indicative of neuronal regeneration (Hynds, 1999). It has 
also been previously discussed that the regulation of growth cones through CSPGs may 
be dependent on the structure and conformation of the CSPG, and that CSPGs may affect 
growth cones by possibly binding directly to the growth cone (Snow, 1996) Surprisingly, 
qPCR data revealed no change in expression of PTPRS, PTPRF, RTN4R, RTN4RL1, and 
RTN4RL2. PTPRS and PTPRF are leukocyte common antigen-related (LAR) subfamily 
of receptors that modulate neuronal development and axonal regeneration (Uetani, 2006). 
PTPRS is a major CSPG receptor in sympathetic neurons, and previous research has 
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revealed that the absence of PTPRS restores axon outgrowth (Gardner, 2013). The results 
depicting no change in PTPRS expression when treated with novel glycans indicate that 
the novel glycans do not affect neurite outgrowth by alterative of PTPRS receptors. 
Furthermore, the results demonstrating the absence of change in expression of PTPRF 
indicate that the novel glycans do not alter neurite outgrowth by interaction of the LAR 
receptors. Previous research has indicated that CSPGs bind to Nogo receptors (RTN4R, 
RTN4RL1, RTN4RL2) for myelin associated growth inhibition (Sharma, 2012). Overall, 
the expression of these genes was not altered at day 7 in vitro; however, it is possible that 
these genes were alters in the first day or two of culture and set the cascade. In order to 
further explore this, the expression of these genes and proteins should be quantified 
throughout the growth periods of culture. Additionally, changes in the function of the 
receptors may need to be tested in order to provide insight on the mechanism of action for 
these novel glycans to allow for neurite outgrowth.   
Previous research regarding CSPGs as neurite outgrowth modulators indicate that 
Nogo receptors are novel receptors for CSPGs, which may provide an insight into the 
mechanism of CSPG inhibition (Dickendesher, 2012). Therefore, it is understandable that 
CSPG inhibition may not be due to decreases in Nogo receptor expression, but due to the 
binding of CSPGs to the receptors itself. PTPRS, another previously identified CSPG 
receptor, plays a role in converting growth cones into a dystrophic state by tightly 
binding them with CSPG substrates, thus bringing a deeper understanding of the role of 
PTPRS in the mediation of growth of neurons (Lang, 2015). With the possibility of 
PTPRS being a possible therapeutic in relieving CSPG-mediated inhibition, our data 
demonstrates that the expression of the genes are not impacted by CSPGs, but rather 
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perhaps the mechanism by which CSPGs interact with PTPRS and other genes may be 
affected.   
Limitations of Experiment 
 Because this study was only conducted in vitro, it is unknown if these novel 
glycans can continue to exhibit its neuroprotective properties in the living system. It is 
important to conduct in vivo testing in order to determine possible side effects and the 
total effects the treatment may have on human health. With this in mind, an in vivo test 
with induced glial scarring following injury may provide monumental data and 
information regarding glycans influence on breaking down the CS/KSPG barrier formed 
following TBI or SCI. Additionally, this study could have also been done in vitro with 
astrocytes present to help recapitulate more of the cellular dynamics one would expect to 
see if the astrocytes would respond to the glycans and thereby alter neurons indirectly.  
Many of the treatments changed in cell number, so changes in neurite size could 
be confounded by the cell-number. The number of cells that was plated on the first day 
remained the same in each well. The differences in cell number are likely attributed to 
survival upon plating. However, when performing calculations and data analysis, data 
was normalized to total nuclei coverage to allow distinct separation between cell number 
and neurite outgrowth. This method of analysis reduces confounding variables, however 
we cannot rule out that differences in growth may be influenced by changes in cell 




 Further directions include investigation of novel glycan structure, to perhaps 
understand the mechanism behind the interaction of novel sulfated glycans and neurite 
outgrowth. Since sulfation patterns directly influence conformation and dynamics, 
continuing to elucidate sulfation pattern structure-function in novel glycans may be 
important in understanding ECM interactions. Addressing the variation in novel glycan 
sulfation patterns, size, dynamics, and conformation by utilizing liquid-state nuclear 
magnetic resonance (NMR), spectroscopy, scalar coupling constant, nuclear overhauser 
effect (NOE) profiles, and other models of analysis to explore the dynamics of molecular 
interactions in neurite regeneration. Investigation of a combination of differentiating 
sulfation patterns and neurite growth promoting abilities of novel glycans can allow for 
further investigation of the structure of those that rescued structure the most in response 
to neurite growth inhibition due to CS/KSPGs.  
In vivo testing will provide further insight into possible biomedical functions of 
the novel sulfated glycans, and may help determine what glycan provides the best 
potential for neurite growth, plasticity, and differentiation.  Further analysis of growth 
cone shape and size may provide further insight on the mechanism of the interaction of 
novel glycans with neurite outgrowth. Filopodia projections have been linked to dendrite 
creation when new synapses are formed in the brain, while lamellipodia seem designed 
for persistent protrusion over a surface.  
Analysis of changes of dendritic spines may provide further insight into the 
plasticity of neurite outgrowth and the mechanism by which novel glycans may allow for 
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neurite outgrowth. Dendritic spines are considered as excitatory postsynaptic sites that 
express high levels of plasticity, and morphology of spines correlate with the level of 
plasticity (De Vivo, 2013).  
The size and shape of spines correlate with calcium kinetics in the spines, which 
may be significant for regulating the communication between synapses (Hering, 2002). 
Specifically, filopodial protrusions indicate novel excitatory synapses, and filopodial 
protrusions become increasingly sparse as maturation furthers (De Vivo, 2013). 
Meanwhile, the shorter spine necks of mushroom and stubby spines may also be of 
importance. Therefore, classification of spines based on size by cup shape, mushroom, 
stubby, thin, and filopodium, as well as calcium signaling, may provide further insight 
into the mechanism behind the novel glycans’ impact on neurite outgrowth.  
Previous studies have demonstrated that CSPGs restrain motility of dendritic 
spines, and that degradation of CSPGs allow for the potentiation of existing synapses (De 
Vivo, 2013). With this in mind, we hypothesize that analysis of dendritic spines of 
neurite treated with CSPGs such as aggrecan and novel glycans will ultimately lead to 
potentiation of synapses and increased motility of dendritic spines.  
Overall Conclusions 
 Sulfated glycans, both from marine life and other sources, possess significant 
potential to outcompete the growth inhibitory CS/KSPG barrier. The exact molecular 
mechanism by which these glycans exert their neurostimulatory effects is unknown, but 
further studies of glycan structure and sulfation may provide more insight into the 
 35 
mechanism. Results may tentatively provide an insight on the mechanism of neurite 
inhibition and regeneration, as well as cell-to-cell communication in the central nervous 
system. This may open the opportunity for a greater understanding of proteoglycans as 
critical regulators of cell structure in plants and animals, and may allow for further 
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